INS and type 1 diabetes mellitus: These β-like cells have been responsive to some of the anti-diabetic pharmaceuticals that are known to accelerate insulin production (Bourgeois et al., 2021), and suggests that stem cell-induced-β-like cells from T1D patients can be used not only for the treatment of diabetes but also for personalized drug screening and studies around drug processing.